💞 #Gate Square Qixi Celebration# 💞
Couples showcase love / Singles celebrate self-love — gifts for everyone this Qixi!
📅 Event Period
August 26 — August 31, 2025
✨ How to Participate
Romantic Teams 💑
Form a “Heartbeat Squad” with one friend and submit the registration form 👉 https://www.gate.com/questionnaire/7012
Post original content on Gate Square (images, videos, hand-drawn art, digital creations, or copywriting) featuring Qixi romance + Gate elements. Include the hashtag #GateSquareQixiCelebration#
The top 5 squads with the highest total posts will win a Valentine's Day Gift Box + $1
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.